151751-Najiba-Chargi

309 Systemic therapy: skeletal muscle mass and oropharyngeal carcinoma 14. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on defi- nition and diagnosis: Report of the euro- pean working group on sarcopenia in older people. Age Ageing. 2010;39(4):412-423. doi: 10.1093/ageing/afq034 [doi]. 15. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastroin- testinal tracts: A population-based study. Lancet Oncol. 2008;9(7):629-635. doi: 10.1016/S1470-2045(08)70153-0 [doi]. 16. Carneiro IP, Mazurak VC, Prado CM. Clini - cal implications of sarcopenic obesity in cancer. Curr Oncol Rep. 2016;18(10):5. doi: 10.1007/s11912-016-0546-5 [doi]. 17. Rier HN, Jager A, Sleijfer S, Maier AB, Levin MD. The prevalence and prognostic value of low muscle mass in cancer patients: A review of the literature. Oncologist. 2016;21(11):1396-1409. doi: 10.1634/the - oncologist.2016-0066 [doi]. 18. Levolger S, van Vugt JL, de Bruin RW, IJzer - mans JN. Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. Br J Surg. 2015;102(12):1448-1458. doi: 10.1002/bjs.9893 [doi]. 19. Pamoukdjian F, Bouillet T, Levy V, Soussan M, Zelek L, Paillaud E. Prevalence and pre - dictive value of pre-therapeutic sarcope- nia in cancer patients: A systematic review. Clin Nutr. 2018;37(4):1101-1113. doi: S0261- 5614(17)30249-2 [pii]. 20. Wendrich AW, Swartz JE, Bril SI, et al. Low SMM is a predictive factor for chemother- apy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26-33. doi: S1368- 8375(17)30129-X [pii]. 21. Achim V, Bash J, Mowery A, et al. Prog - nostic indication of sarcopenia for wound complication after total laryngecto - my. JAMA Otolaryngol Head Neck Surg. 2017;143(12):1159-1165. doi: 10.1001/ja - maoto.2017.0547 [doi]. 22. Bril SI, Pezier TF, Tijink BM, Janssen LM, Braunius WW, de Bree R. Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy. Head Neck. 2019. doi: 10.1002/hed.25638 [doi]. 23. Tamaki A, Manzoor NF, Babajanian E, Ascha M, Rezaee R, Zender CA. Clinical significance of sarcopenia among patients with ad- vanced oropharyngeal cancer. Otolaryngol Head Neck Surg. 2018:194599818793857. doi: 10.1177/0194599818793857 [doi]. 24. Gregoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:184. doi: 10.1093/annonc/mdq185 [doi]. 25. Swartz JE, Pothen AJ, Wegner I, et al. Fea - sibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol. 2016; 62:28-33. doi: S1368-8375(16)30163-4 [pii]. 26. Bril SI, Wendrich AW, Swartz JE, et al. In - terobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical ver- tebra. Eur Arch Otorhinolaryngol. 2019. doi: 10.1007/s00405-019-05307-w [doi]. 27. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin em - bedded head and neck cancer specimen. Int J Cancer. 2007;121(11):2465-2472. doi: 10.1002/ijc.22980 [doi]. 16